Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "Carpal Tunnel Release Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Carpal Tunnel Release Systems was estimated at US$604.4 Million in 2023, and is projected to reach US$809.7 Million by 2030, growing at a CAGR of 4.3% from 2023 to 2030. The growth in the carpal tunnel release systems market is driven by several factors, including technological advancements, an increase in the prevalence ...

It has been about a month since the last earnings report for Conmed (CNMD) . Shares have added about 13.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. CONMED Q2 Earnings Beat, Sales Rise Y/Y, '24 View CutC ...

CONMED Corporation (CNMD) delivered adjusted earnings per share (EPS) of 98 cents in the second quarter of 2024, which beat the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line improved 18.1% from the year-ago quarter’s level.GAAP EPS for the quarter was 96 cents compared with 43 cents per share in the year-ago period.The company’s shares have lost 14.7% in the past six months against the industry’s rise of 1.5%. The broader S&P 500 Index has gained 11.7% in the same time frame.Image Source: Za ...

产品线结构 - 公司产品线包括正骨外科和普通外科，其中正骨外科占总销售额的42%-44%，普通外科占57%-58%[140,141] 收入结构 - 公司约84%的收入来自单次使用产品的销售，资本设备销售也带来了持续的相关单次使用产品和配件的收入[142] 成本压力 - 公司面临着较高的制造和运营成本,主要受到通胀压力和持续的供应链挑战的影响,预计这些挑战将持续到2024年[143] 正骨外科业务 - 公司的正骨外科销售在三个月内下降0.9%,但在六个月内增长0.9%,主要受到某些产品供应链制约的影响,但BioBrace和可视化产品保持增长[154] 普通外科业务 - 公司的普通外科销售在三个月和六个月内分别增长8.9%和8.4%,主要得益于AirSeal和胆道产品线的增长[155] 毛利率 - 公司毛利率在三个月和六个月内分别提高160个和200个基点,主要由于产品组合更加有利以及去年同期因In2Bones收购而产生的存货公允价值摊销成本[156,157] 销售及管理费用 - 公司销售及管理费用占销售额的比重在三个月和六个月内分别下降390个和420个基点,主要得益于或有对价公允价值调整收益、终止分销协议费用以及新仓储管理系统实施成本的减少[158] 研发投入 - 公司第二季度研发费用为1.41亿美元，占净销售额的4.2%，较上年同期略有下降[160] 财务费用 - 公司第二季度利息费用为960万美元，较上年同期下降4%，主要由于平均借款余额下降所致[161] - 公司第二季度的有效税率为20.1%，较上年同期下降1.1个百分点，主要由于2024年收入较高导致税费占比下降以及与或有对价相关的公允价值调整不需缴纳联邦税[163] 现金流 - 公司第二季度经营活动产生的现金流为7240万美元，较上年同期增加约5000万美元，主要由于应收账款回款时间提前以及应付账款支付时间推迟[167,168] - 公司第二季度投资活动使用的现金流较上年同期减少420万美元，主要由于资本支出减少[169] - 公司第二季度筹资活动使用的现金流为6110万美元，较上年同期增加4670万美元，主要由于偿还了7000万美元的2.625%票据以及支付了3940万美元的或有对价[170] 财务状况 - 公司在2024年6月30日的可用信贷额度为5.214亿美元[173] - 公司已回购了610万股共计1.626亿美元的股票，剩余3740万美元可用于未来回购[176]

For the quarter ended June 2024, Conmed (CNMD) reported revenue of $332.1 million, up 4.6% over the same period last year. EPS came in at $0.98, compared to $0.83 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $334.56 million, representing a surprise of -0.74%. The company delivered an EPS surprise of +6.52%, with the consensus EPS estimate being $0.92.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

Conmed (CNMD) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.83 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.52%. A quarter ago, it was expected that this medical technology company would post earnings of $0.74 per share when it actually produced earnings of $0.79, delivering a surprise of 6.76%.Over the last four quarters, the ...

Investor Presentation Q2 2024 Earnings Call Curt R. Hartman Chair of the Board, President, and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer July 31, 2024 Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forwardlooking statements herein or ...

财务业绩 - 第二季度销售额为3.321亿美元，同比增长4.5%，以恒定汇率计算同比增长5.2%[3] - 国内收入同比增长6.1%[19]，国际收入同比增长2.6%，以恒定汇率计算同比增长4.0%[19] - 经调整每股摊薄净收益为0.98美元，同比增长18.1%[28] - 全年收入预期介于13.05亿美元至13.15亿美元之间，较之前指引下调[5] - 全年经调整每股摊薄净收益预期介于3.95美元至4.02美元之间，较之前指引下调[6] - 单次性产品销售同比增长5.5%，资本产品销售同比下降0.3%[18] - 公司报告总营收为6.55亿美元，同比增长5.2%[33] - 公司调整后毛利率为55.5%，同比提升2.3个百分点[37] - 公司调整后净利润为5.54亿美元，同比增长18.5%[37] - 公司调整后每股收益为1.78美元，同比增长19.5%[37] - 公司调整后EBITDA为12.09亿美元，同比增长11.0%[46] - 公司调整后EBITDA利润率为18.8%，同比提升1个百分点[47] 业务发展 - 正在应对供应链挑战，致使商业复苏速度放缓[4] - 公司将继续专注于为客户提供服务并推动长期高于市场的增长[4] - 国内销售占比55.8%，国际销售占比44.2%[19] - 公司完成了对In2Bones Global, Inc.和Biorez, Inc.的收购整合[35][41] - 公司实施了仓储管理软件系统升级项目[35][41] - 公司终止了部分经销商协议并进行了相关重组[35][41] 非GAAP财务指标 - 公司分析净销售额的常汇率基础是一种非GAAP指标，用于更好地衡量不同时期业绩的可比性[51] - 公司剔除了影响可比性和盈利趋势的某些项目，以更一致和可比的方式衡量业绩表现[51] - 非GAAP财务指标无法与其他公司的同类指标进行比较，不应被视为GAAP指标的替代品[52] - 公司无法量化预期每股摊薄收益与经调整每股摊薄收益之间的差异，因为无法合理预测收购、整合及其他费用的影响[53] 其他 - 公司就潜在的设计师佣金问题支付了第三方服务费用[43]

The market expects Conmed (CNMD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Jul ...

CONMED Corporation (CNMD) delivered adjusted earnings per share (EPS) of $0.79 in first-quarter 2024, which beat the Zacks Consensus Estimate of $0.74 by 6.8%. The bottom line improved 19.7% from the year- ago quarter’s level. GAAP EPS for the quarter was 63 cents compared with 6 cents per share in the year-ago period. The company’s shares have lost 25.8% in the past six months against the industry’s rise of 10.0%. The broader S&P 500 Index has gained 23% in the same time frame. Image Source: Zacks Investme ...